4//SEC Filing
Poirier Michael S. 4
Accession 0001493152-20-009959
CIK 0001460702other
Filed
May 26, 8:00 PM ET
Accepted
May 27, 6:04 PM ET
Size
14.4 KB
Accession
0001493152-20-009959
Insider Transaction Report
Form 4
Poirier Michael S.
DirectorChairman, President & CEO.
Transactions
- Other
Warrant (Right to Buy)
2020-05-22+22,142→ 22,142 totalExercise: $2.07From: 2020-05-22Exp: 2024-01-31→ Common Stock (22,142 underlying) - Other
Warrant (Right to Buy)
2020-05-22+14,437→ 14,437 totalExercise: $2.54From: 2020-05-22Exp: 2026-09-22→ Common Stock (14,437 underlying) - Other
Warrant (Right to Buy)
2020-05-22+22,142→ 22,142 totalExercise: $2.54From: 2020-05-22Exp: 2025-03-02→ Common Stock (22,142 underlying) - Other
Common Stock
2020-05-22+169,192→ 169,192 total - Other
Warrant (Right to Buy)
2020-05-22+29,847→ 29,847 totalExercise: $2.07From: 2020-05-22Exp: 2024-08-02→ Common Stock (29,847 underlying)
Footnotes (3)
- [F1]On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer and director of the Issuer.
- [F2]Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 169,192 shares of common stock of the Issuer.
- [F3]Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.
Documents
Issuer
Qualigen Therapeutics, Inc.
CIK 0001460702
Entity typeother
Related Parties
1- filerCIK 0001812504
Filing Metadata
- Form type
- 4
- Filed
- May 26, 8:00 PM ET
- Accepted
- May 27, 6:04 PM ET
- Size
- 14.4 KB